SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
SKBI was delisted on the 18th of December, 2015.
9 hedge funds and large institutions have $1.91M invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
185% more capital invested
Capital invested by funds: $672K → $1.91M (+$1.24M)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
50% more funds holding
Funds holding: 6 → 9 (+3)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
+$306K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$235K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$123K |
| 4 |
SIM
Spark Investment Management
New York
|
+$73.4K |
| 5 |
Citigroup
New York
|
+$6.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$94K |
| 2 |
N
Natixis
Paris,
France
|
-$56K |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$7.35K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$410 |
SKBI Hedge Fund Activity: Q1 2014 in Review
9 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q1 2014, worth a combined $1.91M — up 185% from $672K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SKBI positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Ativo Capital Management, opening a new position worth an estimated $306K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $94K sold.
- 9 institutional investors held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q1 2014, up from 6 in Q4 2013.
- Funds reported $1.91M of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q1 2014, up 185% quarter-over-quarter.
- 5 funds opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q1 2014 and 2 closed out, a net change of +3 holders.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) buyer in Q1 2014 was Ativo Capital Management, an estimated $306K added.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q1 2014 was Virtu KCG Holdings, an estimated $94K sold.
Based on aggregated 13F filings for Q1 2014.